Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Radiation Injuries 1Pancreatic Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 20fludarabine phosphate 16Peripheral Blood Stem Cell Transplantation 11Tacrolimus 10Mycophenolic Acid 10Whole-Body Irradiation 9Cyclosporine 8Methotrexate 7Etoposide 7Busulfan 7Antilymphocyte Serum 7Vincristine 6Prednisone 6Melphalan 6Doxorubicin 5Rituximab 4Transplantation 3Sirolimus 3Radiotherapy 3Methylprednisolone 3Gemcitabine 3Brentuximab Vedotin 3Alemtuzumab 3nelarabine 2merphos 2etoposide phosphate 2Therapeutics 2Prednisolone 2Panobinostat 2Lenalidomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Immunoblastic Lymphadenopathy × Base Sequence × Clear all
NCT01336933 2023-09-22

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

University of Nebraska

Phase 2 Completed
34 enrolled 12 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡